Le Lézard
Classified in: Health, Science and technology
Subject: ACC

DSM - Repurchase of Shares (29 September - 5 October 2017)



HEERLEN, The Netherlands, October 6, 2017 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, has repurchased 140,692 of its own shares in the period from 29 September 2017 up to and including 5 October 2017 at an average price of ?69.52. This is in accordance with the repurchase, covering existing option plans and stock dividends, announced on 14 August 2017. The consideration of this repurchase was ?9.8 million. 

     (Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

The total number of shares repurchased under this program to date is 1,166,876 shares for a total consideration of ?76.7 million.

For more detailed information see the 'Daily transaction details 1.6m Share Repurchase Program announced 14 Aug 2017'.

DSM - Bright Science. Brighter Living.tm 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about ?10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:
DSM Corporate Communications
Stephen Hufton
tel. +31(0)45-5782421        
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31(0)45-5782864
e-mail investor.relations@dsm.com


These press releases may also interest you

at 01:30
reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND's ReS39 therapeutic program of diabetes. This program holds also promise for NASH and the metabolic syndrome.        (Logo:...

at 00:01
Over the last 10 years, the rate of deceased organ donation has increased 42%, according to the latest numbers released by the Canadian Institute for Health Information (CIHI) and Canadian Blood Services. Close to 2,900 lifesaving transplants were...

at 00:01
By almost every measure, Ontario students in grades 7 through 12 are drinking, smoking, and using drugs at the lowest rates since the Ontario Student Drug Use and Health Survey (OSDUHS) began in 1977. This is according to new numbers released today...

13 déc 2017
Half of all individuals in Canada born with cystic fibrosis will not live past around 50 years of age. Emily Lyons ? successful serial entrepreneur and CEO of multiple Toronto-based companies ? experienced firsthand the reality of this sobering...

13 déc 2017
A new study released today by the Pacific Research Institute finds that a program to give discounted prescription drugs to poor Americans is riddled with abuse, has created a perverse incentive for providers to profit instead of effectively serve the...

13 déc 2017
Helix BioPharma Corp. , an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017. FINANCIAL REVIEW...




News published on 6 october 2017 at 03:00 and distributed by: